Stephen Chan, MD, presents real-world data from a systemic review of treatment patterns in the United States of patients with hepatocellular carcinoma from 2020 to 2022.
Medivir AB (MVRBF.PK), a Swedish pharmaceutical company focused on cancer treatments, Tuesday announced that its ongoing phase 1b/2a study with Fostrox + Lenvima demonstrated further improvement in durable clinical benefit in advanced hepatocellular carcinoma or HCC.
An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.
Study in the International Journal of Obesity reveals that BMAL1 deletion in mice protects against obesity and non-alcoholic fatty liver disease caused by a high-fat diet, highlighting its potential as a therapeutic target.
ABK Biomedical successfully secured Breakthrough Device Designation from the FDA on December 5, 2023, for its Eye90 microspheres device, which is indicated for the treatment of.